Resumen

Background: The metabolic syndrome increases cardiovascular mortality. We report the mid-term prognostic value of dobutamine echocardiography for metabolic syndrome. Patients and methods: A dobutamine echocardiography protocol was performed in patients aged 18 years of age or older who suffered from chest pain and who were followed-up for two years. The patients were divided in two groups, with and without metabolic syndrome. Statistical analyses were performed using ROC curves and survival analysis; the Begg-Greenes method was used to correct for verification bias. We included 128 patients, 66 with metabolic syndrome and 62 without. Results: Forty-one patients with metabolic syndrome and 36 without had positive dobutamine echocardiography test results (p = 0.77). Coronary artery disease was found in 27 patients with metabolic syndrome and in 29 without metabolic syndrome; percutaneous revascularization was required in 24 and 26 patients, respectively (p = 0.29). Cardiovascular events occurred in 28 patients during follow-up (19 in metabolic syndrome vs. 9 in non-metabolic syndrome; p = 0.17). The odds ratio of major cardiovascular events in the metabolic syndrome group was 5.8 (95% CI: 1.74-19.60); in the control group it was 8.6 (95% CI: 2.53-29.59). Conclusion: Dobutamine echocardiography for metabolic syndrome has high sensitivity but is not a determining factor for mid-term prognosis.

Palabras clave: Dobutamine echo test metabolic syndrome coronary artery disease diagnostic test

2016-04-19   |   284 visitas   |   Evalua este artículo 0 valoraciones

Vol. 67 Núm.3. Mayo-Junio 2015 Pags. 199-206 Rev Invest Clin 2015; 67(3 ENGLISH)